Morgan Stanley Forecasts Strong Price Appreciation for Merck & Co., Inc. (NYSE:MRK) Stock

Posted by Stanley Muller on Jul 9th, 2026

Merck & Co., Inc. (NYSE:MRK – Get Free Report) had its price target hoisted by analysts at Morgan Stanley from $112.00 to $113.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Morgan Stanley’s target price indicates a potential downside of 9.55% from the stock’s previous close.

Several other research analysts have also recently weighed in on MRK. UBS Group boosted their price target on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Royal Bank Of Canada restated an “outperform” rating and issued a $142.00 price objective on shares of Merck & Co., Inc. in a report on Wednesday. Wells Fargo & Company boosted their price objective on Merck & Co., Inc. from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday. Citigroup began coverage on shares of Merck & Co., Inc. in a research report on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 price target for the company. Finally, Weiss Ratings cut Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 15th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and an average price target of $132.72.

Read Our Latest Report on MRK

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK traded down $1.07 during midday trading on Thursday, reaching $124.92. 3,146,903 shares of the company’s stock traded hands, compared to its average volume of 11,061,420. The company has a market cap of $308.54 billion, a P/E ratio of 35.19, a PEG ratio of 2.75 and a beta of 0.19. The company has a fifty day simple moving average of $118.27 and a two-hundred day simple moving average of $116.06. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. Merck & Co., Inc. has a 1 year low of $76.66 and a 1 year high of $130.29.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. During the same period last year, the firm posted $2.22 earnings per share. The company’s revenue was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Equities analysts predict that Merck & Co., Inc. will post 5.19 EPS for the current fiscal year.

Hedge Funds Weigh In On Merck & Co., Inc.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Brighton Jones LLC increased its holdings in Merck & Co., Inc. by 29.5% in the fourth quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock valued at $3,808,000 after purchasing an additional 8,710 shares during the period. Sivia Capital Partners LLC lifted its stake in shares of Merck & Co., Inc. by 52.2% in the second quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock valued at $910,000 after buying an additional 3,941 shares in the last quarter. Diversify Advisory Services LLC boosted its stake in Merck & Co., Inc. by 94.1% during the 2nd quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company’s stock valued at $2,590,000 after purchasing an additional 15,636 shares during the last quarter. Diversify Wealth Management LLC grew its holdings in Merck & Co., Inc. by 22.2% during the second quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company’s stock worth $3,054,000 after buying an additional 6,897 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Merck & Co., Inc. by 111.7% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company’s stock valued at $53,918,000 after purchasing an additional 359,356 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

Positive Sentiment: Merck received fresh analyst support, including a Wells Fargo price-target increase to $150 and RBC’s reiterated outperform rating with a $142 target, suggesting meaningful upside from current levels. Analyst Target Update
Positive Sentiment: Recent oncology milestones for KEYTRUDA, including U.S. and EU approvals in breast and bladder cancer, reinforce the importance of Merck’s biggest drug franchise and may help offset future patent-expiration concerns. KEYTRUDA Approvals Article
Positive Sentiment: Merck also secured a new HIV access agreement for its once-daily treatment IDVYNSO, adding another incremental growth and commercialization datapoint for investors. HIV Access Deal Article
Neutral Sentiment: Several recent market notes focus on Merck’s valuation and technical setup, with the stock trading above its 50-day and 200-day moving averages; that points to constructive momentum, but not a clear new catalyst by itself. Technical Analysis Article
Neutral Sentiment: Zacks said MRK has been one of its most-watched stocks recently, which highlights elevated investor interest but does not, on its own, change the business outlook. Investor Attention Article
Negative Sentiment: Recent commentary also reminds investors that Merck still faces longer-term headwinds from patent and vaccine pressure, which could limit upside if pipeline execution slows. Top Research Reports Article

About Merck & Co., Inc.

(Get Free Report)

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.